1.Hamed, SA, et al. Vascular risks and complications in diabetes mellitus: the role of helicobacter pylori infection. Journal of Stroke and Cerebrovascular Disease 2008; 17: 86–94.
2.Yoshikawa, H, et al. Involvement of Helicobacter pylori infection and impaired glucose metabolism in the increase of brachial-ankle pulse wave velocity. Helicobacter 2007; 12: 559–566.
3.Herder, C, et al. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Arteriosclerosis, Thrombosis, and Vascular Biology 2006; 26: 2147–2152.
4.Kim, CS, et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. International Journal of Obesity 2006; 30: 1347–1355.
5.Wang, JM, et al. Chemokines and their role in tumor growth and metastasis. Journal of Immunological Methods 1998; 220: 1–17.
6.Benoy, IH, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clinical Cancer Research 2004; 10: 7157–7162.
7.Panichi, V, et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron. Clinical Practice 2006; 102: c51–58.
8.Yamaoka, Y, et al. Relation between cytokines and Helicobacter pylori in gastric cancer. Helicobacter 2001; 6: 116–124.
9.Kusugami, K, et al. Mucosal chemokine activity in Helicobacter pylori infection. Journal of Clinical Gastroenterology 1997; 25 (Suppl. 1): S203–210.
10.Crabtree, JE, et al. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 1991; 32: 1473–1477.
11.Roper, J, et al. Leptin and ghrelin in relation to Helicobacter pylori status in adult males. Journal of Clinical Endocrinology and Metabolism 2008; 93: 2350–2357.
12.Hamajima, N, et al. High anti-Helicobacter pylori antibody seropositivity associated with the combination of IL-8 -251TT and IL-10 -819TT genotype. Helicobacter 2003; 8: 105–110.
13.Hofner, P, et al. Genetic polymorphisms of NOD1 and IL-8, but not polymorphisms of TLR4 genes, are associated with Helicobacter pylori-induced duodenal ulcer and gastritis. Helicobacter 2007; 12: 124–131.
14.Ye, BD, et al. The interleukin-8-251 A allele is associated with increased risk of noncardia gastric adenocarcinoma in Helicobacter pylori-infected Koreans. Journal of Clinical Gastroenterology 2009; 43: 233–239.
15.Ishida, Y, et al. Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A. International Journal of Medical Sciences 2006; 3: 135–140.
16.Fitzgerald, SP, et al. Development of a high-throughput automated analyzer using biochip array technology. Clinical Chemistry 2005; 51: 1165–1176.
17.Hamajima, N, et al. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Japanese Journal of Cancer Research 2000; 91: 865–868.
18.Fukase, K, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial. Lancet 2008; 372: 392–397.
19.Peek, RM Jr, Blaser, MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nature Reviews Cancer 2002; 2: 28–37.
20.Blaser, MJ, Chen, Y, Reibman, J. Does Helicobacter pylori protect against asthma and allergy? Gut 2008; 57: 561–567.
21.Cichoz-Lach, H, et al. Level of serum cytokines in biliary gastritis and erosive gastritis with Helicobacter pylori coinfection. Annales Universitatis Mariae Curie-Skłodowska. Section D: Medicina 2001; 56: 271–274.
22.Mehmet, N, et al. Serum and gastric fluid levels of cytokines and nitrates in gastric diseases infected with Helicobacter pylori. New Microbiologica 2004; 27: 139–148.
23.Russo, F, et al. Circulating cytokines and gastrin levels in asymptomatic subjects infected by Helicobacter pylori (H. pylori). Immunopharmacology and Immunotoxicology 2001; 23: 13–24.
24.Bayraktaroğlu, T, et al. Serum levels of tumor necrosis factor-alpha, interleukin-6 and interleukin-8 are not increased in dyspeptic patients with Helicobacter pylori-associated gastritis. Mediators of Inflammation 2004; 13: 25–28.
25.Di Bonaventura, G, et al. Serum and mucosal cytokine profiles in patients with active Helicobacter pylori and ischemic heart disease: is there a relationship? International Journal of Immunopathology and Pharmacology 2007; 20: 163–172.
26.Innocenti, M, et al. Helicobacter pylori-induced activation of human endothelial cells. Infection and Immunity 2002; 70: 4581–4590.
27.Sieveking, D, Mitchell, HM, Day, AS. Gastric epithelial cell CXC chemokine secretion following Helicobacter pylori infection in vitro. Journal of Gastroenterology and Hepatology 2004; 19: 982–987.
28.Sharma, SA, et al. Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro. Infection and Immunity 1995; 63: 1681–1687.
29.de Jonge, R, et al. The role of Helicobacter pylori virulence factors in interleukin production by monocytic cells. FEMS Microbiology Letters 2001; 196: 235–238.
30.Goll, R, et al. Helicobacter pylori stimulates a mixed adaptive immune response with a strong T-regulatory component in human gastric mucosa. Helicobacter 2007; 12: 185–192.
31.Robinson, K, Argent, RH, Atherton, JC. The inflammatory and immune response to Helicobacter pylori infection. Best Practice & Research. Clinical Gastroenterology 2007; 21: 237–259.
32.Zhang, C, et al. Comparison of Helicobacter pylori infection and gastric mucosal histological features of gastric ulcer patients with chronic gastritis patients. World Journal of Gastroenterology 2005; 11: 976–981.
33.Shirai, K, et al. Interleukin-8 gene polymorphism associated with susceptibility to non-cardia gastric carcinoma with microsatellite instability. Journal of Gastroenterology and Hepatology 2006; 21: 1129–1135.
34.Lee, WP, et al. The -251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clinical Cancer Research 2005; 11: 6431–6441.
35.Kowalski, M, et al. Prevalence of Helicobacter pylori infection in coronary artery disease and effect of its eradication on coronary lumen reduction after percutaneous coronary angioplasty. Digestive and Liver Disease 2001; 33: 222–229.
36.Moyaert, H, et al. Extragastric manifestations of Helicobacter pylori infection: other helicobacters. Helicobacter 2008; 13 (Suppl. 1): 47–57.
37.Miki, K, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterologia Japonica 1987; 22: 133–141.
38.Biemond, I, et al. Serum pepsinogens in patients with gastric diseases or after gastric surgery. Scandinavian Journal of Gastroenterology 1994; 29: 238–242.
39.Oksanen, A, et al. Evaluation of blood tests to predict normal gastric mucosa. Scandinavian Journal of Gastroenterology 2000; 35: 791–795.
40.Ito, Y, et al. Analysis and typing of the vacA gene from cagA-positive strains of Helicobacter pylori isolated in Japan. Journal of Clinical Microbiology 1997; 35: 1710–1714.